Anlotinib for Hepatocellular Carcinoma

• Conditions: Liver Neoplasms

• Registration Number: NCT04954521
• Lead Sponsor: Guangxi Zhuang Autonomous Region People's Hospital

Brief Summary

The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment experience of a wide range of people.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-06
• Study First Submitted: 2021-06-17
• Study First Submitted QC: 2021-06-29
• Last Update Submitted: 2021-06-29
• Study Start: 2021-06-30
• Study First Posted: 2021-07-08
• Last Update Posted: 2021-07-08
• Primary Completion: 2023-07-05
• Study Completion: 2024-07-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Age: ≥ 18 years old, male or female;
2. Patients with advanced liver cancer were diagnosed;
3. Patients assessed by doctors to benefit from single or combined treatment of arotinib;
4. Patients volunteered to join the project.

Exclusion Criteria

None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
OS	From date of admission until the date of death from any cause, assessed up to 24 months	Overall Survival

Secondary Outcome Measures

Name	Time	Method
PFS	From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months	Progression Free Survival

Trial Locations

Locations (1)

People's Hospital of Guangxi Zhuang Autonomous Region; 🇨🇳 Nanning, Guangxi, China